BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolf J, Kalocsai K, Fortuny C, Lazar S, Bosis S, Korczowski B, Petit A, Bradford D, Croos-Dabrera R, Incera E, Melis J, van Maanen R. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clin Infect Dis 2020;71:2581-8. [PMID: 31773143 DOI: 10.1093/cid/ciz1149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Geagan N, Koay WLA. Is There a Future for a Tapered-Pulsed Fidaxomicin Regimen for Pediatric Patients With Recurrent Clostridiodes difficile Infections? J Pediatric Infect Dis Soc 2021;10:1051. [PMID: 34879149 DOI: 10.1093/jpids/piab112] [Reference Citation Analysis]
2 Kociolek LK, Crews JD, Schwenk HT. Recent advances in Clostridioides difficile infection epidemiology, diagnosis and treatment in children. Curr Opin Infect Dis 2021. [PMID: 34232137 DOI: 10.1097/QCO.0000000000000753] [Reference Citation Analysis]
3 Cross SJ, Morton TH, Wolf J. Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children. J Pediatric Infect Dis Soc 2021;10:S46-51. [PMID: 34791397 DOI: 10.1093/jpids/piab078] [Reference Citation Analysis]
4 Conrad MA, Kelsen JR. Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease: A Clinician's Dilemma. J Pediatric Infect Dis Soc 2021:piab069. [PMID: 34343321 DOI: 10.1093/jpids/piab069] [Reference Citation Analysis]
5 Adams DJ, Barone JB, Nylund CM. Community-Associated Clostridioides difficile Infection in Children: A Review of Recent Literature. J Pediatric Infect Dis Soc 2021;10:S22-6. [PMID: 34791398 DOI: 10.1093/jpids/piab064] [Reference Citation Analysis]
6 Marcela K, de Meij GT, Fidelma F, Richard DJ, Mark WH, Ed KJ. How to: Clostridioides difficile infection in children. Clinical Microbiology and Infection 2022. [DOI: 10.1016/j.cmi.2022.03.001] [Reference Citation Analysis]
7 DeVine MN, MacBrayne CE, Child J, Blackmer AB. Pharmacological Management of Pediatric Clostridioides difficile Infection: Clarifying the Controversies. J Pediatr Health Care 2021:S0891-5245(21)00140-1. [PMID: 34412953 DOI: 10.1016/j.pedhc.2021.06.005] [Reference Citation Analysis]
8 Pike CM, Theriot CM. Mechanisms of Colonization Resistance Against Clostridioides difficile. J Infect Dis 2021;223:S194-200. [PMID: 33326565 DOI: 10.1093/infdis/jiaa408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gnocchi M, Gagliardi M, Gismondi P, Gaiani F, De' Angelis GL, Esposito S. Updated Management Guidelines for Clostridioides difficile in Paediatrics. Pathogens 2020;9:E291. [PMID: 32316346 DOI: 10.3390/pathogens9040291] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sattler MM, Crews JD. Challenges in the Diagnosis and Management of Recurrent and Severe Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2021;10:S27-33. [PMID: 34791399 DOI: 10.1093/jpids/piab079] [Reference Citation Analysis]
11 Kociolek LK. Moving the Needle on Clostridioides difficile Research in Children: A Major Step Forward but Challenges Remain. Clin Infect Dis 2020;71:2589-91. [PMID: 31773137 DOI: 10.1093/cid/ciz1154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kociolek LK, Burnham CD, Nicholson MR, Zackular JP. Clostridioides difficile Infection in Children: Research Progress, Pitfalls, and Priorities. J Pediatric Infect Dis Soc 2021;10:S1-2. [PMID: 34791394 DOI: 10.1093/jpids/piab090] [Reference Citation Analysis]
13 Skinner AM, Scardina T, Kociolek LK. Fidaxomicin for the treatment of Clostridioides difficile in children. Future Microbiol 2020;15:967-79. [PMID: 32715754 DOI: 10.2217/fmb-2020-0104] [Reference Citation Analysis]
14 Alonso CD, Maron G, Kamboj M, Carpenter PA, Gurunathan A, Mullane K, Dubberke ER. American Society for Transplantation and Cellular Therapy Series: #5 - Management of Clostridioides difficile infection in hematopoietic cell transplant recipients. Transplant Cell Ther 2022:S2666-6367(22)00093-8. [PMID: 35202891 DOI: 10.1016/j.jtct.2022.02.013] [Reference Citation Analysis]
15 Gonzales-Luna AJ, Carlson TJ, Garey KW. Antibiotic Therapies for Clostridioides difficile Infection in Children. J Pediatric Infect Dis Soc 2021;10:S52-7. [PMID: 34791393 DOI: 10.1093/jpids/piab059] [Reference Citation Analysis]
16 Ye L, Zhang J, Xiao W, Liu S. Efficacy and mechanism of actions of natural antimicrobial drugs. Pharmacol Ther 2020;216:107671. [PMID: 32916205 DOI: 10.1016/j.pharmthera.2020.107671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Barbar R, Hayden R, Sun Y, Tang L, Hakim H. Epidemiologic and Clinical Characteristics of Clostridioides difficile Infections in Hospitalized and Outpatient Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients. Pediatr Infect Dis J 2021;40:655-62. [PMID: 34097657 DOI: 10.1097/INF.0000000000003126] [Reference Citation Analysis]